Literature DB >> 9361744

Immune response to Trypanosoma cruzi shed acute phase antigen in children from an endemic area for Chagas' disease in Bolivia.

S F Brenière1, N Yaksic, J Telleria, M F Bosseno, F Noireau, P Wincker, D Sanchez.   

Abstract

A field study of the immune response to the shed acute phase antigen (SAPA) of Trypanosoma cruzi was carried out in the locality of Mizque, Cochabamba department, Bolivia. Schoolchildren (266), with an average of 8.6 +/- 3.6 years, were surveyed for parasitological and serological diagnosis, as well as antibodies directed against SAPA using the corresponding recombinant protein in ELISA. The antibodies against SAPA were shown in 82% of patients presenting positive serological diagnosis (IgG specific antibodies). The positive and negative predictive values were 0.88. Antibodies anti-SAPA were shown in 80.8% of the chagasic patients in the initial stage of the infection (positive IgM serology and/or positive buffy coat (BC) test) and in 81.4% of the patients in the indeterminate stage of the infection (positive IgG serology with negative BC and IgM tests). These results show that the anti-SAPA response is not only present during the initial stage of the infection (few months) but extends some years after infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361744     DOI: 10.1590/s0074-02761997000400011

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

1.  Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia.

Authors:  Caryn Bern; Manuela Verastegui; Robert H Gilman; Carlos Lafuente; Gerson Galdos-Cardenas; Maritza Calderon; Juan Pacori; Maria Del Carmen Abastoflor; Hugo Aparicio; Mark F Brady; Lisbeth Ferrufino; Noelia Angulo; Sarah Marcus; Charles Sterling; James H Maguire
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

2.  Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries.

Authors:  Eufrosina S Umezawa; Alejandro O Luquetti; Gabriela Levitus; Carlos Ponce; Elisa Ponce; Diana Henriquez; Susana Revollo; Bertha Espinoza; Octavio Sousa; Baldip Khan; José Franco da Silveira
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Early diagnosis of congenital Trypanosoma cruzi infection, using shed acute phase antigen, in Ushuaia, Tierra del Fuego, Argentina.

Authors:  María Cristina Mallimaci; Sergio Sosa-Estani; Graciela Russomando; Zunilda Sanchez; Carina Sijvarger; Isabel Marcela Alvarez; Lola Barrionuevo; Carlos Lopez; Elsa Leonor Segura
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

4.  Trypomastigote Excretory Secretory Antigen Blot Is Associated With Trypanosoma cruzi Load and Detects Congenital T. cruzi Infection in Neonates, Using Anti-Shed Acute Phase Antigen Immunoglobulin M.

Authors:  Sassan Noazin; Jessica A Lee; Edith S Malaga; Edward Valencia Ayala; Beth J Condori; Cristian Roca; Andres G Lescano; Caryn Bern; Walter Castillo; Holger Mayta; Maria Carmen Menduiña; Manuela R Verastegui; Freddy Tinajeros; Robert H Gilman
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

Review 5.  ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

Authors:  Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga
Journal:  BMC Infect Dis       Date:  2010-11-25       Impact factor: 3.090

6.  Evaluation of UMELISA CHAGAS™ with the incorporation of new monomeric and chimeric peptides representative of different regions of Trypanosoma cruzi

Authors:  Idialis Hernández; Milenen Hernández; Jeny González; Ivonne Gómez; Orlando Zulueta; Grisell Ramos; Darien Ortega; Dunia Clara Bequer; Giosvany Ernesto Martínez; Aurora Delahanty
Journal:  Biomedica       Date:  2021-05-31       Impact factor: 0.935

Review 7.  Chagas' disease: pregnancy and congenital transmission.

Authors:  Ana María Cevallos; Roberto Hernández
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.